Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Assets Average (2016 - 2026)

Ocular Therapeutix has reported Assets Average over the past 13 years, most recently at $770.3 million for Q1 2026.

  • For Q1 2026, Assets Average rose 78.34% year-over-year to $770.3 million; the TTM value through Mar 2026 reached $770.3 million, up 78.34%, while the annual FY2025 figure was $633.0 million, 78.31% up from the prior year.
  • Assets Average for Q1 2026 was $770.3 million at Ocular Therapeutix, up from $609.5 million in the prior quarter.
  • Over five years, Assets Average peaked at $770.3 million in Q1 2026 and troughed at $125.6 million in Q2 2023.
  • A 5-year average of $346.1 million and a median of $395.5 million in 2024 define the central range for Assets Average.
  • Biggest five-year swings in Assets Average: crashed 30.38% in 2023 and later surged 320.51% in 2024.
  • Year by year, Assets Average stood at $153.9 million in 2022, then skyrocketed by 34.62% to $207.2 million in 2023, then skyrocketed by 128.81% to $474.2 million in 2024, then rose by 28.54% to $609.5 million in 2025, then rose by 26.39% to $770.3 million in 2026.
  • Business Quant data shows Assets Average for OCUL at $770.3 million in Q1 2026, $609.5 million in Q4 2025, and $431.1 million in Q3 2025.